ACH ACCENDRA HEALTH INC/VA/

CIK 0000075252 50 ready 8-Ks latest August 17, 2026, 6:42 AM ET RSS · JSON

Activity: ELEVATED 4 filings / 30d vs 2 baseline

Ready 8-Ks 50

Latest filing August 17, 2026, 6:42 AM ET

Top materiality 0.90

Event mix earnings ×12 · debt ×11 · leadership ×9

Sentiment 9 pos · 9 neg · 32 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for ACH

Highest-materiality recent filing

Owens & Minor completes $375M sale of P&HS segment to Platinum Equity; will rename to Accendra Health

December 31, 2025, 6:59 PM ET M&A materiality 0.90 positive item 1.01 item 2.01 item 2.03 item 5.02 item 5.03 item 7.01 item 9.01 ◈ Governance Changes ×2◈ Debt Financings◈ M&A Transactions◈ Material Agreements

Sale closed for $375M cash, plus 5% retained equity and preserved tax attributes >$150M.
Company renamed Accendra Health, Inc.; new ticker ACH starts Jan 2, 2026.

Read filing →

August 17, 2026, 6:42 AM ET other material materiality 0.65 positive item 7.01 item 9.01

Accendra Health scraps ATM program, sells non-core assets for $45M, targets CEO successor by mid-September

Company will not implement at-the-market equity program; no impact on results or published guidance.
August 10, 2026, 4:15 PM ET other material materiality 0.50 neutral item 1.01 item 3.03 item 5.03 item 7.01 item 9.01

Accendra Health adopts Section 382 Rights Plan to protect NOLs; triggers at 4.9% stake

Board declares dividend of one preferred share purchase right per common share; record date Aug 20, 2026.
August 10, 2026, 6:50 AM ET earnings materiality 0.85 negative item 2.02 item 7.01 item 9.01

Accendra Health Q2 revenue down 10%, adjusted loss; CEO Pesicka to retire by end of 2026

Q2 net revenue $613.2M, down 10% YoY from $681.9M; GAAP EPS -$1.16 vs -$1.09.
August 10, 2026, 6:36 AM ET leadership materiality 0.70 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change

Accendra Health CEO Ed Pesicka to retire by end of 2026; board starts successor search

CEO Edward A. Pesicka to retire by end of 2026; will also step down from board.
June 25, 2026, 4:15 PM ET debt materiality 0.70 neutral item 8.01 item 9.01

Accendra Health closes exchange offers: 99.9% of 2029 notes and 99.2% of 2030 notes tendered

Tendered $478.3M of 2029 notes (99.9%) and $548.0M of 2030 notes (99.2%).
June 15, 2026, 4:15 PM ET debt materiality 0.80 negative item 1.01 item 2.03 item 8.01 item 9.01 ◈ Debt Financings ×4◈ Material Agreements

Accendra Health exchanges nearly all outstanding notes for new secured notes at 9%-9.75% rates

Approximately 99.9% of 2029 Notes ($478.3M) and 99.2% of 2030 Notes ($547.9M) tendered and accepted early.
May 22, 2026, 4:08 PM ET debt materiality 0.70 negative item 7.01 item 9.01

Accendra Health launches exchange offer for 4.5%/6.625% notes; new 9%/9.75% secured notes

Offer to exchange $478.7M of 4.500% 2029 notes and $552.2M of 6.625% 2030 notes for secured notes.
May 15, 2026, 8:30 AM ET other materiality 0.25 neutral item 5.02 item 5.07 ◈ Shareholder Votes ×4

Accendra shareholders elect six directors, ratify KPMG, approve 2023 incentive plan amendment

All six director nominees elected with votes for ranging from 48.8M to 51.2M; broker non-votes 9.8M.
May 11, 2026, 7:59 PM ET earnings materiality 0.85 negative item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Accendra Health Q1 revenue $627.8M, adj. EBITDA $58.4M; >$1.5B debt optimization

Q1 revenue $627.8M (down 6.8% YoY); GAAP loss from cont. ops $6.5M vs $3.8M loss prior year.
May 11, 2026, 7:59 PM ET debt materiality 0.85 negative item 1.01 item 7.01 item 9.01 ◈ Material Agreements

Accendra Health launches $326.25M 9% first lien notes, $300M revolver, and exchange offers for existing notes

New $326.25M 9.000% Senior Secured First Lien Notes due 2032 and $300M revolver due 2030.
February 19, 2026, 6:59 PM ET earnings materiality 0.75 neutral item 2.02 item 7.01 item 9.01

Accendra Health Q4 revenue $709M; GAAP loss narrows to $9.4M; completes P&HS sale

Revenue from continuing ops $709M (up 2% YoY); full-year revenue $2.76B (+3% YoY).
January 5, 2026, 6:59 PM ET M&A materiality 0.75 negative item 9.01

Accendra Health closes P&HS sale for $375M cash; pro forma revenue falls to $2.68B

Sold P&HS business for $375M cash on Dec 31, 2025; proceeds used to repay $280M current debt.
December 31, 2025, 6:59 PM ET M&A materiality 0.90 positive item 1.01 item 2.01 item 2.03 item 5.02 item 5.03 item 7.01 item 9.01 ◈ Governance Changes ×2◈ Debt Financings◈ M&A Transactions◈ Material Agreements

Owens & Minor completes $375M sale of P&HS segment to Platinum Equity; will rename to Accendra Health

Sale closed for $375M cash, plus 5% retained equity and preserved tax attributes >$150M.
December 18, 2025, 6:59 PM ET other material materiality 0.60 neutral item 5.02 item 7.01 item 9.01

Owens & Minor to rename as Accendra Health; ticker changes to ACH on Jan 2, 2026

Name change to Accendra Health, Inc. effective Dec 31, 2025; NYSE ticker becomes "ACH" on Jan 2, 2026.
December 8, 2025, 6:59 PM ET leadership materiality 0.50 neutral item 5.02 item 7.01

Appoints Perry A. Bernocchi as COO effective Dec 5; CHRO Stone to depart Dec 31, role eliminated

Perry A. Bernocchi, age 67, appointed EVP, COO effective Dec 5, 2025; previously led Patient Direct segment.
December 2, 2025, 6:59 PM ET other materiality 0.10 neutral item 7.01 item 9.01

Owens & Minor management to present at Citi and BofA conferences on Dec 2, 2025

Ed Pesicka (CEO) and Will Parrish (VP) to speak at Citi 2025 Global Healthcare Conference on Dec 2.
October 30, 2025, 7:59 PM ET M&A materiality 0.85 positive item 2.02 item 7.01 item 9.01

Owens & Minor to sell Products & Healthcare segment; Q3 adjusted EPS $0.25

Signed definitive agreement to sell Products & Healthcare Services segment, pivoting to pure-play home-based care.
October 7, 2025, 7:59 PM ET M&A materiality 0.80 positive item 1.01 item 7.01 item 9.01

Owens & Minor sells P&HS segment to Platinum Equity for $375M cash + retained equity

Cash payment of $375 million at closing, subject to customary adjustments for working capital, net debt, and expenses.
September 19, 2025, 7:59 PM ET leadership materiality 0.35 neutral item 5.02

Owens & Minor CIO Snehashish Sarkar resigns effective Sept 26, 2025

Snehashish Sarkar, EVP and Chief Information Officer, resigns effective September 26, 2025 to pursue an external opportunity.
August 11, 2025, 7:59 PM ET earnings materiality 0.75 neutral item 2.02 item 7.01 item 9.01

Owens & Minor Q2: GAAP loss from continuing ops $83.8M; Products & Healthcare segment classified as discontinued ops

Revenue from continuing ops $681.9M, up 3% YoY from $660.4M.
June 6, 2025, 7:59 PM ET debt materiality 0.75 neutral item 2.04 ◈ Debt Financings

Owens & Minor to redeem $1B in 10% notes due 2030 after Rotech merger termination

Merger agreement to acquire Rotech terminated effective June 5, 2025.
June 5, 2025, 7:59 PM ET M&A materiality 0.85 negative item 1.01 item 1.02 item 8.01 item 9.01

Owens & Minor terminates $80M Rotech acquisition; will redeem $1B notes

Mutual termination of merger agreement; OMI pays $80M termination fee to Rotech.
May 16, 2025, 7:59 PM ET other material materiality 0.10 neutral item 5.07

Owens & Minor shareholders elect nine directors, ratify KPMG, approve say-on-pay at 2025 meeting

All nine director nominees elected with >65M votes for each; broker non-votes of ~5.2M.
May 8, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

Owens & Minor Q1 adj EPS $0.23, revenue $2.63B; reaffirms FY guide, active on P&HS sale

Adjusted EPS $0.23 vs $0.19 YoY; GAAP net loss $(0.32) per share vs $(0.29).
April 4, 2025, 7:59 PM ET debt materiality 0.70 neutral item 1.01 item 2.03 item 9.01 ◈ Debt Financings

Owens & Minor closes $1B 10% senior secured notes offering to fund Rotech acquisition

$1,000,000,000 aggregate principal of 10.000% senior secured notes due 2030 issued.
April 2, 2025, 7:59 PM ET debt materiality 0.70 neutral item 7.01 item 9.01

Owens & Minor upsizes and prices $1B of 10.000% senior secured notes due 2030

Upsized to $1B aggregate principal at 10.000% interest, maturing April 15, 2030.
March 26, 2025, 7:59 PM ET debt materiality 0.65 neutral item 7.01 item 8.01 item 9.01

Owens & Minor launches $600M senior secured notes offering to finance Rotech acquisition

Launched $600M senior secured notes due 2030 in a private placement to QIBs and non-U.S. persons.
March 20, 2025, 7:59 PM ET other material materiality 0.15 neutral item 7.01 item 9.01

Owens & Minor furnishes lender presentation; no material updates disclosed

Investor presentation dated March 20, 2025, furnished for use in meetings with lenders.
February 28, 2025, 6:59 PM ET earnings materiality 0.80 neutral item 2.02 item 7.01 item 9.01

Owens & Minor reports Q4 GAAP net loss $296M, adjusted EPS $0.55; exploring sale of P&HS segment

Q4 GAAP net loss $296M ($3.84 loss per share); adjusted net income $43M ($0.55 EPS).
February 3, 2025, 6:59 PM ET earnings materiality 0.75 negative item 2.02 item 7.01 item 9.01

Owens & Minor: preliminary Q4 net loss ~$300M, $310M goodwill impairment; launches financing for Rotech acquisition

Q4 prelim rev $2.67-2.70B; net loss $(288-311)M; adj EBITDA $135-140M; adj EPS $0.52-0.55.
November 5, 2024, 6:59 PM ET other materiality 0.20 neutral item 5.02

Owens & Minor amends deferred comp plan; employer match and contributions now discretionary

Amendment to Executive Deferred Compensation and Retirement Plan effective January 1, 2025.
November 4, 2024, 6:59 PM ET earnings materiality 0.65 neutral item 2.02 item 7.01 item 9.01

Owens & Minor Q3 revenue up 5% to $2.7B; GAAP net loss $0.17/shr; adj EPS $0.42; debt cut $198M

Consolidated revenue of $2.7B (+5% YoY); GAAP net loss $(13M) or $(0.17)/share.
October 22, 2024, 7:59 PM ET debt materiality 0.50 neutral item 1.01 item 2.03 item 9.01

Owens & Minor enters $450M receivables sale facility with PNC; replaces 2020 agreement

Up to $450M of accounts receivable sold on a limited-recourse basis; proceeds for general corporate purposes.
October 15, 2024, 7:59 PM ET regulatory materiality 0.60 neutral item 8.01

Owens & Minor receives FTC Second Request for Rotech acquisition; closing expected H1 2025

Company and Rotech received FTC Second Request on October 11, 2024, extending HSR Act waiting period.
September 23, 2024, 7:59 PM ET leadership materiality 0.50 neutral item 5.02 item 9.01 ◈ executive_change

Owens & Minor appoints Jonathan Leon as permanent CFO effective Sept 23, 2024

Leon, interim CFO since June 2024, named EVP, CFO with annual salary of $550,000.
September 16, 2024, 7:59 PM ET debt materiality 0.35 neutral item 8.01

Owens & Minor redeems $171.3M of 4.375% Senior Notes due 2024

Redeemed all $171,322,000 aggregate principal of 4.375% Senior Notes due 2024 on September 16, 2024.
August 2, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 7.01 item 9.01

Owens & Minor Q2 revenue up 4% to $2.7B; adjusted EPS doubles to $0.36; agrees to acquire Rotech

Revenue $2.67B (+4% YoY); GAAP net loss $32M ($0.42 loss per share) vs. $28M loss last year.
July 31, 2024, 7:59 PM ET debt materiality 0.60 neutral item 7.01

Owens & Minor calls all $171.3M of 4.375% Senior Notes due 2024 for redemption

Full redemption of 4.375% Senior Notes due 2024 on September 16, 2024 at 100% of principal plus accrued interest.
July 23, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Owens & Minor reports preliminary Q2 GAAP net loss $0.42-0.46/share, adj. EPS $0.32-$0.36; reaffirms FY guidance

Revenue $2,651-$2,671M; GAAP net loss per share $(0.42)-$(0.46); adjusted EPS $0.32-$0.36.
July 23, 2024, 7:59 PM ET M&A materiality 0.85 positive item 1.01 item 7.01 item 9.01

Owens & Minor to buy Rotech for $1.36B cash; expects ~$0.15 EPS accretion in second year

Purchase price $1.36B cash; net $1.32B after ~$40M tax benefits; ~6.3x LTM EBITDA ex-synergies.
June 24, 2024, 7:59 PM ET leadership materiality 0.60 negative item 5.02 ◈ executive_change ×2

Owens & Minor CFO Bruni resigns at company's request; interim CFO Leon appointed

Alexander J. Bruni resigned as EVP & CFO effective June 21, 2024, will remain until Sep 5, 2024 for transition.
May 24, 2024, 7:59 PM ET leadership materiality 0.30 neutral item 5.02 ◈ executive_change

Owens & Minor names Jennifer Stone EVP & CHRO effective June 3, 2024

Jennifer Stone (53) appointed Executive Vice President & Chief Human Resources Officer.
May 10, 2024, 7:59 PM ET other materiality 0.20 neutral item 5.02 item 5.07 ◈ Shareholder Votes ×4

Owens & Minor shareholders approve plan amendment, elect nine directors at annual meeting

Shareholders elected nine director nominees with majority support; votes for ranged from 66.8M to 67.4M shares.
May 9, 2024, 7:59 PM ET leadership materiality 0.25 neutral item 5.02 ◈ executive_change

Owens & Minor promotes Snehashish Sarkar to EVP & CIO

Snehashish Sarkar (49) named Executive Vice President & Chief Information Officer effective May 9, 2024.
May 3, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Owens & Minor Q1 adj EPS $0.19 (4x YoY); revenue $2.61B up 4%

Adj EPS $0.19 vs $0.05 YoY; GAAP net loss per share $(0.29) vs $(0.32).
April 22, 2024, 7:59 PM ET leadership materiality 0.30 neutral item 5.02 ◈ executive_change

Owens & Minor EVP Dan J. Starck to retire effective May 17, 2024

Dan J. Starck, EVP of Business Excellence, notified the Company of his retirement.
March 1, 2024, 6:59 PM ET other material materiality 0.10 neutral item 5.02 item 9.01

Owens & Minor adopts PSU agreement form for 2023 Omnibus Incentive Plan

Approved form performance stock units under 2023 Omnibus Incentive Plan on Feb 28, 2024.
February 20, 2024, 6:59 PM ET earnings materiality 0.75 neutral item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Owens & Minor Q4 adjusted EPS $0.69, revenue $2.66B; full year operating cash flow $741M

Q4 GAAP net income $17.8M vs loss of $58.0M; adjusted net income $53.6M vs $21.7M.
December 15, 2023, 6:59 PM ET leadership materiality 0.30 neutral item 5.02 ◈ executive_change

Owens & Minor EVP and CHRO Tammy L. Gomez resigns effective Dec 15, 2023

Tammy L. Gomez, EVP and Chief Human Resources Officer, resigns on Dec 11, 2023, effective Dec 15, 2023.
December 6, 2023, 6:59 PM ET other material materiality 0.70 positive item 7.01 item 9.01

Owens & Minor sets 2028 targets: revenue >$12B, adj. EPS >$3.50, 20%+ CAGR

2028 revenue target exceeding $12 billion; adjusted EBITDA above $750 million.

Executive changes

Departed

Edward A. Pesicka

President, Chief Executive Officer & Director

ACH · ACCENDRA HEALTH INC/VA/

Filed: August 10, 2026, 6:36 AM ET

On August 10, 2026, Accendra Health, Inc. (the “Company”) announced that Edward A. Pesicka, President, Chief Executive Officer & Director of the Company, notified the board of directors (the “Board”) of the Company of his intention to retire and step down from the Board by the end of 2026, or such earlier time as a successor is appointed.

Appointed

Jonathan A. Leon

Executive Vice President, Chief Financial Officer

ACH · ACCENDRA HEALTH INC/VA/

Effective: 2024-09-23
Filed: September 23, 2024, 7:59 PM ET

On September 23, 2024, Owens & Minor, Inc. (the “Company”) announced that Jonathan A. Leon, age 58, has been appointed Executive Vice President, Chief Financial Officer of the Company, effective September 23, 2024.

Departed

Alexander J. Bruni

Executive Vice President & Chief Financial Officer

ACH · ACCENDRA HEALTH INC/VA/

Effective: 2024-06-21
Successor: Jonathan A. Leon
Filed: June 24, 2024, 7:59 PM ET

Alexander J. Bruni, the Company’s Executive Vice President & Chief Financial Officer, has, at the request of the Company, resigned from his position as an officer of the Company, effective June 21, 2024.

Appointed (interim)

Jonathan A. Leon

Interim Chief Financial Officer

ACH · ACCENDRA HEALTH INC/VA/

Effective: 2024-06-21
Filed: June 24, 2024, 7:59 PM ET

Jonathan A. Leon, the Company’s Senior Vice President, Corporate Treasurer, has been appointed as interim Chief Financial Officer effective June 21, 2024.

Appointed

Jennifer Stone

Executive Vice President & Chief Human Resources Officer

ACH · ACCENDRA HEALTH INC/VA/

Effective: 2024-06-03
Filed: May 24, 2024, 7:59 PM ET

On May 24, 2024, Owens & Minor, Inc. (the Company) named Jennifer Stone (53) Executive Vice President & Chief Human Resources Officer of the Company effective June 3, 2024.

Role change

Snehashish Sarkar

Executive Vice President & Chief Information Officer

ACH · ACCENDRA HEALTH INC/VA/

Effective: 2024-05-09
Filed: May 9, 2024, 7:59 PM ET

On May 9, 2024 Owens & Minor, Inc. (the Company) named Snehashish Sarkar (49) Executive Vice President & Chief Information Officer of the Company.

Departed

Dan J. Starck

Executive Vice President, Business Excellence

ACH · ACCENDRA HEALTH INC/VA/

Effective: 2024-05-17
Filed: April 22, 2024, 7:59 PM ET

On April 16, 2024, Dan J. Starck, Executive Vice President, Business Excellence of Owens & Minor, Inc. (the “Company”), informed the Company that he was retiring from his position at the Company, effective May 17, 2024.

Departed

Tammy L. Gomez

Executive Vice President and Chief Human Resources Officer

ACH · ACCENDRA HEALTH INC/VA/

Effective: 2023-12-15
Filed: December 15, 2023, 6:59 PM ET

On December 11, 2023, Tammy L. Gomez, Executive Vice President and Chief Human Resources Officer of Owens & Minor, Inc. (the “Company”), informed the Company that she was resigning from her position at the Company, effective December 15, 2023, to accept a position with a large industrial conglomerate.

Appointed

Heath H. Galloway

Executive Vice President, General Counsel and Corporate Secretary

ACH · ACCENDRA HEALTH INC/VA/

Effective: 2023-05-17
Filed: April 19, 2023, 7:59 PM ET

The Company has named Heath H. Galloway (46) as Executive Vice President, General Counsel and Corporate Secretary effective upon Mr. Pace’s departure.

Departed

Nicholas J. Pace

Executive Vice President, General Counsel and Corporate Secretary

ACH · ACCENDRA HEALTH INC/VA/

Effective: 2023-05-17
Successor: Heath H. Galloway
Filed: April 19, 2023, 7:59 PM ET

On April 13, 2023, Nicholas J. Pace, Executive Vice President, General Counsel and Corporate Secretary of Owens & Minor, Inc. (the “Company”), informed the Company that he was resigning from his position at the Company, effective May 17, 2023, to accept a role as executive vice president & general counsel with a privately-held revenue cycle management company.

Appointed

Alexander J. Bruni

Executive Vice President & Chief Financial Officer

ACH · ACCENDRA HEALTH INC/VA/

Effective: 2022-10-12
Filed: October 12, 2022, 7:59 PM ET

Alexander J. Bruni, age 46, has been appointed Executive Vice President & Chief Financial Officer of the Company replacing Mr. Long effective October 12, 2022.

Role change

Andrew G. Long

Executive Vice President, Chief Executive Officer of Products & Healthcare Services Segment

ACH · ACCENDRA HEALTH INC/VA/

Effective: 2022-10-12
Successor: Alexander J. Bruni
Filed: October 12, 2022, 7:59 PM ET

Andrew G. Long, the Company’s Executive Vice President & Chief Financial Officer has been appointed as Executive Vice President, Chief Executive Officer of the Company’s Products & Healthcare Services segment, effective October 12, 2022.

Earnings & guidance

2026-Q1 EPS reported -$0.08 filing →

Materiality & sentiment trend

Max materiality 0.90 · Median 0.68 · Most common event earnings

9 positive 9 negative 32 neutral

source · ACH on sec.gov